- Innovation
- Pharmaceuticals
- Strategy
Innovation & Collaboration
Bayer's Pharmaceuticals Division is committed to advancing pharmaceutical innovation in China and addressing patients' unmet medical needs. Since establishing its global R&D center in China in 2009, Bayer has integrated China into its global R&D network, helping bring innovative medicines to Chinese patients faster. To date, nearly 20 innovative medicines, around 40 new indications and new formulations have been approved in China.
Bayer is deeply integrated into China's innovation ecosystem and continues to strengthen and expand external partnerships. In 2009, Bayer signed a strategic partnership agreement with Tsinghua University, pioneering research collaboration between a multinational pharmaceutical company and a Chinese academic institution, while supporting scientific innovation in China and accelerating the translation of research discoveries into new medicines. In 2014, Bayer established a long-term strategic research partnership with Peking University. To date, Bayer has conducted more than 100 joint research projects with these two leading Chinese universities.
Long-Term Strategic Partnerships with Leading Chinese Academic Institutions
Through the Bayer E-Town Open Innovation Center and the Bayer Co.Lab China, Bayer has established a dual-engine innovation ecosystem in China's cutting-edge life sciences sector. By supporting and nurturing early-stage innovation, Bayer connects innovation from China with global expertise, helping accelerate the development of breakthrough therapies and bring more innovations originating in China to patients around the world.